AMGEN PRESENTS NEW AMG 133 PHASE 1 CLINICAL DATA …
https://www.amgen.com/newsroom/press-releases/2022/12/amgen-presents-new-amg-133-phase-1-clinical-data-at-wcirdc-2022
WEBDec 1, 2022 · Initiating Phase 2 Study in Early 2023. THOUSAND OAKS, Calif., Dec. 1, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new Phase 1 data from AMG 133, a novel bispecific glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and glucagon-like peptide-1 (GLP-1) receptor agonist molecule.
DA: 80 PA: 66 MOZ Rank: 46 Up or Down: Up